Shankhadip Nandi*

Department of Pharmaceutics, Eminent College of Pharmaceutical Technology, Kolkata, West Bengal, India

*Corresponding Author: Shankhadip Nandi, Assistant Professor, Department of Pharmaceutics, Eminent College of Pharmaceutical Technology, Kolkata, West Bengal, India.

Received: April 25, 2023; Published: June 01, 2023

Conventional formulations have been often failed to achieve patient compliance due to their poor drug solubility, uncontrollable release profile, side effects, lack of site selectivity, and low bioavailability [1]. Across the laboratories, scientists are extremely committed to break down the fences between the available most promising new drug candidates and their targets towards cells or tissues. To do this, they have been developed a few novel drug delivery modalities. Eventually, the following novel drug delivery modalities intend to translate the scientific progress into clinical benefits for human welfare.

References

1. Faheem AM and Abdelkader DH. “Novel drug delivery systems”. Engineering Drug Delivery Systems (2020): 1-16.
2. Xu L., et al. “Lipid nanoparticles for drug delivery”. Advanced NanoBiomed Research2 (2022): 2100109.
3. Khalil IA., et al. “Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids”. Biological and Pharmaceutical Bulletin 4 (2020): 584-595.
4. Aliakbarinodehi N., et al. “Interaction kinetics of individual mRNA-containing lipid nanoparticles with an endosomal membrane mimic: dependence on pH, protein corona formation, and lipoprotein depletion”. ACS Nano12 (2022): 20163-20173.
5. Zhao Z., et al. “Targeting strategies for tissue-specific drug delivery”. Cell1 (2020): 151-167.
6. Zhang L., et al. “Engineered ultrasmall nanoparticle drug‐immune conjugates with “hit and run” tumor delivery to eradicate gastric cancer”. Advanced Therapeutics3 (2023): 2200209.
7. Adepu S and Ramakrishna S. “Controlled drug delivery systems: current status and future directions”. Molecules19 (2021): 5905.
8. Biologics Global Market Report 2023. The Business Research Company (2023).
9. Pechenov S., et al. “Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease”. Scientific Reports 11 (2021): 22521.
10. Gennemark P., et al. “An oral antisense oligonucleotide for PCSK9 inhibition”. Science Translational Medicine 13 (2021): 593.

Citation

Citation: Shankhadip Nandi. “Exploring the Next Generation of Novel Drug Delivery Technologies". Acta Scientific Pharmaceutical Sciences 7.7 (2023): 01-02.

Copyright

Copyright: © 2023 Shankhadip Nandi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.